vimarsana.com
Home
Live Updates
Can-Fite Reports 2022 Financial Results & Provides Clinical Update : comparemela.com
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory
Related Keywords
United States ,
Russia ,
Israel ,
Ukraine ,
Romania ,
American ,
Russian ,
Pnina Fishman ,
Motti Farbstein ,
Fite Biopharma ,
Kiryat Matalon ,
Soroka Medical Center ,
Trademark Office Granted Can ,
Exchange Commission ,
Clinical Development Highlights ,
Company Annual Report On Form ,
Fite Biopharma Ltd ,
European Medicines Agency ,
Drug Administration ,
Can Fite Biopharma ,
Clinical Development Highlights Include ,
Trial Met Primary Endpoint ,
Psoriasis Area ,
Severity Index ,
Registration Plan ,
Piclidenoson Submitted ,
Topical Psoriasis Treatment ,
Significantly Inhibit Pancreatic Cancer ,
Preclinical Studies ,
Trademark Office Granted Can Fite ,
Liver Fibrosis ,
Treating Fibrotic Liver Tissue Using ,
Advanced Clinical Studies ,
Cancer Study ,
Complete Response ,
Advanced Liver Cancer Treated ,
Compassionate Use ,
Decompensated Liver Cirrhosis Will Be Treated ,
Namodenoson Under Compassionate Use ,
Annual Report ,
Can Fite Investor Relations ,
Orphan Drug Designation ,
Fast Track Designation ,
Ifite ,
Reports ,
022 ,
Financial ,
Results ,
Rovides ,
Linical ,
Update ,
comparemela.com © 2020. All Rights Reserved.